Skip to main content
Erschienen in: Clinical Rheumatology 1/2012

01.01.2012 | Original Article

How common is methotrexate pneumonitis? A large prospective study investigates

verfasst von: Navtej Sathi, Batsirai Chikura, Viswanath V. Kaushik, Rose Wiswell, Julie K. Dawson

Erschienen in: Clinical Rheumatology | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

The current literature states the prevalence of methotrexate pneumonitis (MTX-P) to be 3.5–7.6%. This is based on retrospective data. Consequently, clinicians remain cautious in using methotrexate especially in patients with pre-existing lung disease. To get a true idea of the incidence of MTX-P we designed an ongoing prospective study, which is the largest to date. We recruited all patients starting low-dose methotrexate in our department, and followed them up for 2 years or until development of MTX-P. All patients had their pulmonary spirometry checked at baseline. Patients were excluded if they did not give consent for methotrexate therapy, or had a forced expiratory volume in 1 s (fev1) or full vital capacity (FVC) of less than 1 l. So far, 223 patients have been recruited of whom 223 have completed 6 months and 185 have finished 2 years of follow-up from commencing methotrexate. Only two patients developed MTX-P. This gave an incidence of one case every 192 patient years of MTX-P. The results of this ongoing prospective study suggest that MTX-P when diagnosed using Carson’s criteria and Chest HRCT scanning, does not occur as often as previously thought. Also it would appear from our data that baseline spirometry rather than full pulmonary function tests can be used routinely as an immediate screening of lung function prior to commencement of methotrexate. Interestingly the patients who developed MTX-P did not have any specific abnormalities at baseline.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Chikura B, Sathi N, Dawson JK (2009) Methotrexate Induced Pneumonitis: a review article. Current Respiratory Medicine Reviews 5(1):12–20 Chikura B, Sathi N, Dawson JK (2009) Methotrexate Induced Pneumonitis: a review article. Current Respiratory Medicine Reviews 5(1):12–20
2.
Zurück zum Zitat McKendry RJ, Dale P (1993) Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. J Rheumatol 20:1850–1856PubMed McKendry RJ, Dale P (1993) Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. J Rheumatol 20:1850–1856PubMed
3.
Zurück zum Zitat Carson CW, Cannon GW, Egger MJ, Ward JR, Clegg DO (1987) Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthritis Rheum 16:186–195PubMedCrossRef Carson CW, Cannon GW, Egger MJ, Ward JR, Clegg DO (1987) Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthritis Rheum 16:186–195PubMedCrossRef
4.
Zurück zum Zitat Sostman HD, Matthay RA, Putman CE, Smith GJ (1976) Methotrexate-induced pneumonitis. Medicine (Baltimore) 55:371–388CrossRef Sostman HD, Matthay RA, Putman CE, Smith GJ (1976) Methotrexate-induced pneumonitis. Medicine (Baltimore) 55:371–388CrossRef
5.
Zurück zum Zitat Bourke SJ. Lecture Notes on Respiratory Medicine: Chapter 3 p. 20 Blackwell Publishing Ltd. Osney Mead, Oxford, OX2 0EL, UK Bourke SJ. Lecture Notes on Respiratory Medicine: Chapter 3 p. 20 Blackwell Publishing Ltd. Osney Mead, Oxford, OX2 0EL, UK
6.
Zurück zum Zitat Hanranhan PS, Scrivens GA, Russell AS (1989) Prospective long term follow-up of methotrexate therapy in rheumatoid arthritis: toxicity, efficacy and radiological progression. Br J Rheum 28:147–153CrossRef Hanranhan PS, Scrivens GA, Russell AS (1989) Prospective long term follow-up of methotrexate therapy in rheumatoid arthritis: toxicity, efficacy and radiological progression. Br J Rheum 28:147–153CrossRef
7.
Zurück zum Zitat Drosos AA, Psychos D, Andonopoulos AP et al (1990) Methotrexate therapy in rheumatoid arthritis: a two year prospective follow up. Clin Rheumatol 9:333–341PubMedCrossRef Drosos AA, Psychos D, Andonopoulos AP et al (1990) Methotrexate therapy in rheumatoid arthritis: a two year prospective follow up. Clin Rheumatol 9:333–341PubMedCrossRef
8.
Zurück zum Zitat Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR (2001) Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computered tomography, chest radiography, and pulmonary function tests. Thorax 56:622–627PubMedCrossRef Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR (2001) Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computered tomography, chest radiography, and pulmonary function tests. Thorax 56:622–627PubMedCrossRef
9.
Zurück zum Zitat Dawson JK, Graham DR, Desmond J, Fewins HE, Lynch MP (2002) Investigation of the chronic pulmonary effects of low dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology 41:262–267PubMedCrossRef Dawson JK, Graham DR, Desmond J, Fewins HE, Lynch MP (2002) Investigation of the chronic pulmonary effects of low dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology 41:262–267PubMedCrossRef
10.
Zurück zum Zitat Searles G, McKendry RJ (1987) Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheumatol 14:1164–1171PubMed Searles G, McKendry RJ (1987) Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheumatol 14:1164–1171PubMed
11.
Zurück zum Zitat Frank SI, Weg JG, Harkleroas LE, Fitch RF (1973) Pulmonary dysfunction in rheumatoid disease. Chest 63:27–34PubMedCrossRef Frank SI, Weg JG, Harkleroas LE, Fitch RF (1973) Pulmonary dysfunction in rheumatoid disease. Chest 63:27–34PubMedCrossRef
12.
Zurück zum Zitat Perez T, Farre JM, Gosset P, Wallaert B, Duquesnoy B, Voisin C, Delcambre B, Tonnel AB (1989) Subclinical alveolar inflammation in rheumatoid arthritis: superoxide anion, neutrophil chemotactic activity and fibronectin generation by alveolar macrophages. Eur Respir J 2:7–13PubMed Perez T, Farre JM, Gosset P, Wallaert B, Duquesnoy B, Voisin C, Delcambre B, Tonnel AB (1989) Subclinical alveolar inflammation in rheumatoid arthritis: superoxide anion, neutrophil chemotactic activity and fibronectin generation by alveolar macrophages. Eur Respir J 2:7–13PubMed
13.
Zurück zum Zitat Saag KG, Kolluri S, Koehnke RK et al (1996) Rheumatoid arthritis lung disease: determinants of radiographic and physiologic abnormalities. Arthritis Rheum 39:1711PubMedCrossRef Saag KG, Kolluri S, Koehnke RK et al (1996) Rheumatoid arthritis lung disease: determinants of radiographic and physiologic abnormalities. Arthritis Rheum 39:1711PubMedCrossRef
14.
Zurück zum Zitat Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, Corte TJ, Sander CR, Ratoff J, Devaraj A, Bozovic G, Denton CP, Black CM, du Bois RM, Wells AU (2008) Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 177(11):1248–1254PubMedCrossRef Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, Corte TJ, Sander CR, Ratoff J, Devaraj A, Bozovic G, Denton CP, Black CM, du Bois RM, Wells AU (2008) Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 177(11):1248–1254PubMedCrossRef
Metadaten
Titel
How common is methotrexate pneumonitis? A large prospective study investigates
verfasst von
Navtej Sathi
Batsirai Chikura
Viswanath V. Kaushik
Rose Wiswell
Julie K. Dawson
Publikationsdatum
01.01.2012
Verlag
Springer-Verlag
Erschienen in
Clinical Rheumatology / Ausgabe 1/2012
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-011-1758-6

Weitere Artikel der Ausgabe 1/2012

Clinical Rheumatology 1/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.